Date: 2026-05-15Category: Press ReleaseState: Union GovernmentCountry: India
Indian Pharmacopoeia Commission organizes Scientific Conclave & Interactive Session on Indian Pharmacopoeia 2026 at the National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana
**Executive Summary**
On 15 May 2026, the Indian Pharmacopoeia Commission (IPC) hosted a Scientific Conclave at NIPER Hyderabad to discuss the "Indian Pharmacopoeia 2026" and the role of reference and impurity standards. The event brought together regulatory, clinical, and industrial experts to address the clinical implications of impurities and patient safety. The primary objective was to strengthen medicine quality systems through the development and implementation of robust pharmacopoeial standards.
**Key Points / Main Content**
**Event Overview and Objectives**
* The conclave focused on the theme "Significance of Indian Pharmacopoeia Reference Standards and Impurity Standards in Ensuring Pharmaceutical Quality."
* Organized by the IPC in collaboration with NIPER Hyderabad, the Central Drugs Standard Control Organization (CDSCO), and the IDMA Telangana Chapter.
* The initiative supports the "Viksit Bharat" vision by enhancing medicine quality systems and quality assurance mechanisms.
**Technical and Regulatory Focus**
* Discussions centered on impurity profiling as an essential component for reducing adverse drug reactions and ensuring patient safety.
* Technical sessions covered advancements in the Indian Pharmacopoeia 2026, including impurity reference standards and risk assessment approaches.
* Experts deliberated on regulatory compliance, analytical methodologies, and emerging global concerns in pharmaceutical impurity management.
**Collaboration and Engagement**
* The conclave represented the first time IPC brought together experts from clinical, analytical, industrial, and regulatory backgrounds to discuss pharmacopoeial impurities.
* The event provided a platform for pharmaceutical industries to share experiences regarding the development, adoption, and implementation of Indian Pharmacopoeia Reference Substances (IPRS).
* The session emphasized the importance of harmonized standards and regulatory oversight in safeguarding public health.
**Impact Analysis**
**Pharmaceutical Industry**
**Impact**
Companies are affected by the evolving standards for impurity control and the introduction of new Indian Pharmacopoeia Reference Substances (IPRS).
**Action Required**
Industries must actively adopt and implement IPRS and impurity standards while aligning their quality control processes with the advancements in Indian Pharmacopoeia 2026.
**Regulators (IPC, CDSCO, and State Licensing Authorities)**
**Impact**
Regulators are responsible for providing oversight and ensuring harmonized standards are maintained across the sector to protect public health.
**Action Required**
They must continue to facilitate scientific exchange, provide regulatory guidance on impurity management, and oversee the implementation of robust pharmacopoeial standards.
**Academia and Researchers**
**Impact**
These stakeholders benefit from platforms for scientific exchange and capacity building in pharmaceutical quality initiatives.
**Action Required**
Academia and researchers need to collaborate with regulatory bodies like the IPC to advance analytical methodologies and research related to impurity profiling.
**Clinicians**
**Impact**
Clinicians are now integrated into discussions regarding how pharmacopoeial impurities and standardizations directly affect adverse drug reactions and patient safety.
**Action Required**
Clinicians should contribute clinical perspectives to the deliberation of impurity standards to help identify potential associations between impurities and patient safety concerns.
Key Entities Referenced
Indian Pharmacopoeia Commission (IPC): An autonomous institution under the Ministry of Health and Family Welfare responsible for setting official standards for the quality, safety, and efficacy of medicines in India.
Indian Pharmacopoeia 2026: The forthcoming edition of the Indian Pharmacopoeia, representing the updated official standards for pharmaceutical substances and preparations.
Central Drugs Standard Control Organization (CDSCO): India's national regulatory body for pharmaceuticals and medical devices, involved in the oversight of drug quality and regulatory compliance.
Indian Pharmacopoeia Reference Substances (IPRS): Official reference standards and impurity standards used to ensure the pharmaceutical quality and purity of medicines.
NIPER Hyderabad, Telangana: A premier national institute of pharmaceutical education and research that served as the venue and primary academic collaborator for the conclave.
Ministry of Health and Family Welfare
Indian Pharmacopoeia Commission organizes
Scientific Conclave & Interactive Session on
Indian Pharmacopoeia 2026 at the National
Institute of Pharmaceutical Education and
Research (NIPER), Hyderabad, Telangana
Importance of Indian Pharmacopoeia Reference Standards
and Impurity Standards in Ensuring the Quality of Medicines
Highlighted at Conclave
Conclave Brings Together Pharmaceutical Quality, Clinical,
Regulatory and Industry Experts for the First Time to
Deliberate on Clinical Implications of Pharmacopoeial
Impurities and Patient Safety
Posted On: 15 MAY 2026 6:18PM by PIB Delhi
The Indian Pharmacopoeia Commission (IPC), Ministry of Health and Family Welfare, Government of
India, organized a Scientific Conclave & Interactive Session on Indian Pharmacopoeia 2026 today at the
National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, Telangana, in
collaboration with NIPER Hyderabad, Central Drugs Standard Control Organization (CDSCO), and the
IDMA Telangana Chapter. The conclave focused on the theme “Significance of Indian Pharmacopoeia
Reference Standards and Impurity Standards in Ensuring Pharmaceutical Quality.”The IPC, mandated with promoting the quality, safety, and rational use of medicines, continues to
undertake initiatives aimed at strengthening pharmaceutical quality and safeguarding patient safety.
Recognizing that the quality of medicines remains a critical component of public health protection, IPC
has been consistently addressing issues related to pharmaceutical quality through scientific, regulatory,
and stakeholder engagement platforms. The present conclave was organized to deliberate upon the
significance of Indian Pharmacopoeia Reference Substances (IPRS) and impurity standards in ensuring
the quality, safety, and efficacy of medicines.
The conference was formally inaugurated by Prof. Shailendra Saraf, Director, NIPER Hyderabad, who
appreciated IPC for collaborating with academic institutions in advancing pharmaceutical quality
initiatives. He highlighted that such collaborations with premier institutions, including NIPER Hyderabad
and previously NIPER Ahmedabad, provide an important platform for scientific exchange and capacity
building among regulators, academia, and industry stakeholders.Dr. V. Kalaiselvan, Secretary-cum-Scientific Director, IPC, emphasized that impurity profiling and
scientifically established pharmacopoeial standards are essential components in reducing adverse effects
associated with pharmaceutical impurities. He reiterated IPC’s commitment towards strengthening
medicine quality systems and contributing to the vision of “Viksit Bharat” through robust pharmacopoeial
standards and quality assurance mechanisms.
The inaugural session was attended by senior officials from IPC, CDSCO, NIPER Hyderabad, and the
pharmaceutical industry. Shri K. Narendran, Deputy Drugs Controller (India), CDSCO, Hyderabad, also
addressed the gathering and highlighted the importance of harmonized standards and regulatory oversight
in ensuring medicine quality.
A unique feature of the conclave was the participation of stakeholders from both the pharmaceutical
quality and clinical domains. For the first time, IPC brought together experts from regulatory, analytical,
industrial, and clinical backgrounds to deliberate upon the clinical implications of pharmacopoeial
impurities, including their potential association with adverse drug reactions and patient safety concerns.
The conclave also provided an important opportunity for pharmaceutical industries actively involved in
the development, adoption, and implementation of IPRS and impurity standards to share their experiences
and perspectives.
During the technical sessions, experts from IPC, CDSCO, academia, and the pharmaceutical industry
deliberated upon contemporary issues related to pharmacopoeial standards, impurity control, regulatory
compliance, advancements in Indian Pharmacopoeia 2026, impurity reference standards, pharmaceutical
quality assurance, risk assessment approaches, and emerging global concerns in pharmaceutical impurity
management and regulatory control
The conclave concluded with an interactive open discussion involving experts from IPC, CDSCO, State
Licensing Authorities, academia, clinicians, researchers, and industry representatives on various aspects of
pharmaceutical impurities, analytical methodologies, regulatory expectations, and implementation
challenges.
The conference was well attended by regulators, pharmaceutical industry professionals, academicians,
clinicians, analytical scientists, and researchers from across the country, reaffirming IPC’s continued
commitment towards strengthening medicine quality systems and promoting public health protection
through scientifically robust pharmacopoeial standards.*****
SR
HFW–IPC 2026 Scientific Conclave at NIPER Hyderabad/15th May 2026/1
(Release ID: 2261510) Visitor Counter : 224
Read this release in: Telugu , Urdu , ही , Tamil